indomethacin embryofetopathy
Findings
No curated finding names indomethacin embryofetopathy yet. Everything below is reference data from Mondo, HPO and GenCC, not evidence about what affects it.
Definition
Indomethacin embryofetopathy refers to the manifestations that may be observed in a fetus or newborn when the mother has taken indomethacin, a potent prostaglandin inhibitor and tocolytic agent that can cross placenta, during pregnancy. Reported adverse fetal/neonatal effects include decreased renal function resulting in oligohydramnios, closure of the ductus arteriosus, and delayed cardiovascular adaptation at birth. These effects are usually transient and reversible. Indomethacin may also be a risk factor for cerebral injury (periventricular leukomalacia) and necrotizing enterocolitisin preterm infants.
Definition from the Mondo Disease Ontology (MONDO:0016005), read 2026-09-29. CC BY 4.0.
Features
12 features
What the disease is reported to present with, and how often among people who have it — never how often a feature means the disease. HPO, annotations 2026-09-02.
- NephropathyHPOHP:0000112
- Very frequent (80% to 99% of cases)
- Premature birthHPOHP:0001622
- Very frequent (80% to 99% of cases)
- Renal insufficiencyHPOHP:0000083
- Very frequent (80% to 99% of cases)
- Respiratory insufficiencyHPOHP:0002093
- Very frequent (80% to 99% of cases)
- Abnormal renal tubule morphologyHPOHP:0000091
- Occasional (5% to 29% of cases)
- Abnormality of coagulationHPOHP:0001928
- Occasional (5% to 29% of cases)
Where it sits
Other names
2 names
Resolves to: indomethacin embryofetopathy
- Also called
- fetal indomethacin syndromefoetal indomethacin syndrome